NBIX - Neurocrine Biosciences, Inc.
After hours:
| Previous close | 92.18 |
| Open | 92.44 |
| Bid | 91.29 x 800 |
| Ask | 92.92 x 800 |
| Day's range | 91.19 - 93.77 |
| 52-week range | 88.38 - 129.29 |
| Volume | |
| Avg. volume | 701,946 |
| Market cap | 8.901B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 147.13 |
| EPS (TTM) | 0.62 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 124.67 |
Simply Wall St.Are Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
It is hard to get excited after looking at Neurocrine Biosciences' (NASDAQ:NBIX) recent performance, when its stock has...
PR NewswireNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of INGREZZA® (valbenazine) capsules evaluating global tardive dyskinesia (TD) improvement and stability of psychiatric symptoms in adults with TD and schizophrenia or schizoaffective disorder. The data (Poster #SA135) was presented at the Schizophrenia International Research Society (SIRS) 2023 Annual Congress in Toronto, Canada.
- PR Newswire
Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new analyses of Phase 2 data of the investigational drug crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) and post hoc analyses of Phase 3 data for EFMODY® (hydrocortisone modified-release hard capsules). EFMODY is approved by the European Commission for the European Economic Area (including N
ZacksNeurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an update on its 2023 financial guidance.
- PR Newswire
Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2023 Healthcare Conference at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) on Tuesday, May 9, 2023. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
PR NewswireNeurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its continued support of increasing awareness regarding the prevalence, impact and importance of screening for tardive dyskinesia (TD), during Tardive Dyskinesia Awareness Week, May 1-7. TD is an involuntary movement disorder associated with prolonged use of certain mental health medicines (antipsychotics) that can be used to treat bipolar disorder, depression, schizophrenia and schizoaffective disorder.1,3,4
ZacksEarnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 3, 2023.
- PR Newswire
Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday, March 28, 2023. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will participate at the conference.
- PR Newswire
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT™, the largest real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia (TD), was published in the Journal of Patient-Reported Outcomes.1 The analysis assessed the effects of possible TD, defined as clinician-confirmed presence of abnormal involuntary movements, on patient health and social functioning. It demonstrated that it's important for clinicians t
- PR Newswire
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of INGREZZA® (valbenazine) capsule contents through soft foods or a gastrostomy (G-tube) feeding tube. The data (Poster #IND03, Valbenazine Capsule Contents for Potential Administration via Soft Food/Feeding Tube) will be presented at AMDA – The Society for Post-Acute and Long-Term Care Medicine's PALTC23 Annual Conference being held March
- PR Newswire
Neurocrine Biosciences to Participate at Investor Conferences in March
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m. Eastern Time on Wednesday, March 15 2023 in Miami. Neurocrine Biosciences will participate in the Jefferies Biotech on the Bay Summit on Thursday, March 16 2023 in Miami.
- PR Newswire
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT™ 3-extension and KINECT™ 4). These data (Poster #NR-36, Improvements Over Time with Long-Term Valbenazine in Older and Elderly Patients with Tardive Dyskinesia) are being presented at the American Association for Geriatric Psychiatry
- GlobeNewswire
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with th
- Simply Wall St.
Neurocrine Biosciences Full Year 2022 Earnings: EPS Misses Expectations
Neurocrine Biosciences ( NASDAQ:NBIX ) Full Year 2022 Results Key Financial Results Revenue: US$1.49b (up 31% from FY...
- Simply Wall St.
Investors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growth
It hasn't been the best quarter for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) shareholders, since the share price...
- PR Newswire
Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on Tuesday, February 14, 2023. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
ZacksNeurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided financial guidance for 2023.
ZacksCatalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Voyager Therapeutics Stock Is Sinking This Week
Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. Rather, Voyager's shares seem to be reverting to the mean following their enormous run-up earlier this month. As a refresher, the biotech's shares spiked by as much as 76% during the first two weeks of January as a result of the company's lucrative gene therapy deal with Neurocrine Biosciences (NASDAQ: NBIX).
- PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 6, 2023.